Dashboard
Manage Tickers

ABBV


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

if-you-invested-100-in-abbvie-stock-10-years-ago-you-would-have-this-much-today
If You Invested $100 In AbbVie Stock 10 Ye...
10/13/2025 21:00:34

Core News & Articles
CNBC Halftime Report Final Trades: AbbVie,...
10/13/2025 17:01:06

abbvie-says-fda-approves-snda-that-updates-indication-statement-for-rinvoq-for-treatment-of-adults-with-uc-and-cd
AbbVie Says FDA Approves sNDA That Updates...
10/13/2025 15:00:29

-        Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking a...

abbvie-to-present-new-adc-data-at-esmo-congress-2025-highlighting-temab-a-abbv-706-and-emrelis-in-difficult-to-treat-tumors
AbbVie To Present New ADC Data At ESMO Con...
10/13/2025 11:18:16

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progre...

piper-sandler-maintains-overweight-on-abbvie-raises-price-target-to-284
Piper Sandler Maintains Overweight on AbbV...
10/10/2025 12:38:43

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $2...

Core News & Articles
A Congress Member Sold Up To $300K In A.O....
10/08/2025 15:00:28

abbvies-botox-shows-improvement-in-movement-disorder-study
AbbVie's Botox Shows Improvement In Moveme...
10/06/2025 14:54:17

AbbVie's Phase 2 ELATE trial shows onabotulinumtoxinA improves tremor scores and meets all endpoints, offering a new option...

abbvies-botox-meets-primary-and-all-secondary-endpoints-in-phase-2-elate-trial-for-upper-limb-essential-tremor
AbbVie's BOTOX Meets Primary And All Secon...
10/06/2025 13:06:06

OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvemen...

abbvie-expects-q3-earnings-to-include-27b-iprd-expense-q3-adj-eps-guidance-range-is-174---178-sees-fy25-adj-eps-guidance-range-including-iprd-impact-is-1038---1058
AbbVie Expects Q3 Earnings To Include $2.7...
10/03/2025 20:14:48

Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D ...

b-of-a-securities-maintains-neutral-on-abbvie-raises-price-target-to-251
B of A Securities Maintains Neutral on Abb...
10/03/2025 13:16:56

B of A Securities analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $220 to...

what-does-the-market-think-about-abbvie-inc
What Does the Market Think About AbbVie Inc?
10/03/2025 13:00:44

reported-earlier-calico-life-sciences-abbvie-announce-joint-developed-abbv-cls-628-monoclonal-antibody-gets-us-fdas-fast-track-designation-for-autosomal-dominant-polycystic-kidney-disease
Reported Earlier: Calico Life Sciences, Ab...
10/02/2025 16:53:21

Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphab...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/01/2025 17:35:33

hsbc-downgrades-abbvie-to-hold
HSBC Downgrades AbbVie to Hold
10/01/2025 17:35:08

HSBC analyst Rajesh Kumar downgrades AbbVie (NYSE:ABBV) from Buy to Hold.

abbvies-allergan-aesthetics-announces-natrelle-has-been-named-a-supplier-by-vizient
AbbVie's Allergan Aesthetics Announces Nat...
10/01/2025 12:11:01

This agreement grants Vizient clients enhanced access to Natrelle®, the broadest selection of breast implant options on the mar...

a-closer-look-at-abbvies-options-market-dynamics
A Closer Look at AbbVie's Options Market D...
09/30/2025 20:01:24

abbvie-begins-70m-expansion-at-abbvie-bioresearch-center-in-worcester-expansion-to-create-new-jobs-and-strengthen-us-manufacturing-footprint-supporting-over-6000-positions
AbbVie Begins $70M Expansion At AbbVie Bio...
09/30/2025 19:06:05

Expansion increases biologics manufacturing for immunology and oncology medicinesMilestone marks progress on AbbVie's long-...

abbvie-submits-biologics-license-application-to-fda-seeking-approval-for-pivekimab-sunirine-to-treat-blastic-plasmacytoid-dendritic-cell-neoplasm
AbbVie Submits Biologics License Applicati...
09/30/2025 12:03:19

AbbVie (NYSE:ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administra...

heres-how-much-100-invested-in-abbvie-5-years-ago-would-be-worth-today
Here's How Much $100 Invested In AbbVie 5 ...
09/29/2025 20:30:30

AbbVie (NYSE: ABBV) has outperformed the market over the past 5 years by 6.25% on an annualized basis producing an average annu...

abbvie-to-start-construction-of-its-new-active-pharmaceutical-ingredient-manufacturing-plant-in-north-chicago-illinois-facility-expected-to-be-fully-operational-and-serving-patients-by-2027
AbbVie To Start Construction Of Its New Ac...
09/29/2025 16:05:26

NORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new ac...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION